Across TCGA pan-cancer cohorts, S100A6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated S100A6 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher S100A6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated S100A6 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, GBM, and LUAD are the cancer types where S100A6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	1.000	0.271	.008	19	view →
GBM	DFS	Quartile	All	0.592	0.823	.001	18	view →
LUAD	DFS	Quartile	II,III,IV	0.362	0.786	.012	10	view →
LSCC	OS	Quartile	III,IV	0.473	0.901	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: S100A6 tumor-vs-normal RNA expression · all S100A6 data types